factors (Ballas 2005) . Vaso-occlusive pain episodes are the most common cause of recurrent morbidity, hospital admissions and work or school absenteeism in people with SCD (Platt 1991) . Approximately 90% of hospital admissions of people with SCD are for treating acute pain (Brozovic 1987) . Hypoxia, dehydration, acidosis, cold exposure and strenuous exercise also can lead to sickling of red blood cells leading to an acute painful episode. Nociceptive sickle cell pain may be acute recurrent painful crises, chronic pain syndromes and neuropathic pain. The acute painful crisis evolves through prodromal, initial, established and resolving phases (Ballas 2012) . Chronic sickle cell pain may be due to avascular necrosis and leg ulcers or intractable pain without any obvious signs. Chronic pain is usually associated with emotional distress, behavioural dysfunction, family stress, financial concern, frequent visits to healthcare providers, heavy use of analgesic medications and fear (Ballas 2005) . Treatment aims for SCD are to relieve pain, prevent infections and manage complications (Stinson 2003) . Despite being the main source of discomfort for people with SCD, therapies for pain crises are not definitive. Pharmacotherapies involve opioids, nonopioids and adjuvants. Non-opioids (e.g. acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs) tramadol and corticosteroids) have a 'ceiling effect' beyond which they are no longer effective, and NSAIDs and corticosteroids have well-known complications such as haemostasis, acute renal failure, congestive heart failure when overused (Niscola 2009 ). Thus opioids are frequently employed, as they have fewer systemic effects. However, their use is plagued with reports of addiction, tolerance and drug-seeking behaviour (Neville 2011) . Moreover, opioids may contribute to the development of acute chest syndrome during an acute sickle cell pain crisis (Buchanan 2005) . These factors have motivated clinicians and researchers worldwide to embrace a multidisciplinary approach towards pain management in people with SCD, with a focus on including non-pharmacological interventions. According to the recommendations of the American Pain Society, pharmacological treatments for SCD should be complimented by psychological, behavioral, and physical modalities (American Pain Society Guidelines 1999).
Description of the intervention
As defined by the American Physical Therapy Association, TENS is the application of electrical stimulation to the skin for pain control. It is non-invasive, inexpensive, safe, and easy to use; a small battery-powered device applies an electric current via two or more non-invasive skin electrodes to stimulate underlying nerves and thus reduce pain perception. It can be applied with different frequencies, varying from low (< 10 Hz) to high (> 50 Hz). Intensity can also vary with low-intensity stimulation producing a sensation alone, while high-intensity stimulation triggers muscle contraction, and hence movement. Low-frequency TENS is usually given at high-intensity (producing motor contraction and sensation), while high-frequency TENS is given at lower intensities (producing both sensation and muscle contraction) (DeSantana 2008) . Conventional TENS has a high-stimulation frequency (40 Hz to 150 Hz) and low intensity between 10 mA to 30 mA. The pulse duration is short (up to 50 microseconds). The onset of analgesia with this setup is virtually immediate. Pain relief lasts while the stimulus is turned on, but it usually abates when the stimulation stops. In acupuncture like settings, the TENS unit delivers low frequency stimulus trains at 1 Hz to 10 Hz, at a high stimulus intensity, close to the tolerance limit of the individual. This method is uncomfortable and is often considered for those who do not respond to conventional TENS. Pulsed (burst) TENS uses lowintensity stimuli firing in high-frequency bursts, but does not have any added advantage over the conventional method. Over the last 40 years, TENS has been evaluated for the management of pain in numerous conditions, including fibromyalgia (Sunshine 1996) rheumatoid arthritis, osteoarthritis, post-caesarean pain, lower back pain (Milne 2004 ) neck pain and numerous other causes. While reviews report that evidence on the efficacy of TENS is inconclusive, magnetic resonance imaging (MRI) studies implicate central pain signal modulation indicating a central action (Kocyigit 2012). There are contraindications for the use of TENS. These include use during pregnancy, as it may induce premature labour, as well as application over the carotid sinuses, due to the risk of acute hypotension through a vasovagal reflex. In addition to these, it should not be placed over the anterior neck, because laryngospasm due to laryngeal muscle contraction may occur, the electrodes should not be placed in an area of sensory impairment, where the possibility of burns exists and a TENS unit should be used cautiously in individuals with a spinal cord stimulator or an intrathecal pump.
How the intervention might work
A variety of mechanisms for the analgesic action of TENS have been suggested, including presynaptic inhibition in the dorsal horn of the spinal cord, endogenous pain control via endorphins, and direct inhibition of nerve excitation and restoration of afferent input (Kaye 2015) . This produces a host of responses, including sensation, movement (muscle contraction), and pain relief. In people with SCD, vaso-occlusion leads to secondary tissue injury which generates several major pain mediators like interleukin-1, bradykinin which in turn sensitize peripheral nerve endings and facilitate the transmission of painful stimuli along A-δ and C fibres that reach the cerebral cortex via the spinal cord and the thalamus (Ballas 2005) . This partly corresponds to the 'gate control theory' (Melzack 1965) for the mechanism of analgesia produced by TENS where the 'open gate' between C fibres and T cells which allow pain transmission centrally is closed by the electrical stimulation to the skin provided by the TENS instrument.
Why it is important to do this review
Over recent years, although considerable knowledge has been gained on the pathophysiological mechanisms of pain and the pharmacogenetics of analgesics (including opioids) there has been not much progress in the clinical management of sickle cell pain. Many adults with SCD still face accusations, assumptions and disbelief about their painful condition which is often wrongly perceived by some healthcare providers as drug-seeking behaviour (Ballas 2014). Mismanagement of pain in SCD may lead to serious psychosocial and physiological consequences, such as depression, low self esteem, anxiety and reduced participation in social activities, resulting in chronic pain interspersed with episodes of acute exacerbations (Smith 2005) . Hence, organizations such as the American Pain Society recommended that pharmacologic treatment for SCD should be complemented by complementary and alternative medicine. Cochrane Reviews on TENS for specific chronic pain conditions have suggested that TENS is more effective than placebo TENS, although methodological weaknesses in randomised controlled trials (RCTs) have sometimes hindered definitive conclusions (Bennett 2011; Brosseau 2003; Johnson 2010; Rutjes 2009 ). Studies carried out on the effect of TENS on neck pain suggested that active TENS may be more effective than placebo TENS (Kroeling 2013). A systematic review on the effect of TENS on cancer pain in adults suggested bone pain on movement may improve in a cancer population on application of TENS, but most of the results remained inconclusive due to a limited number of RCTs included in the review (Hurlow 2012). Most reviews of TENS therapy are inconclusive at present, which is why a standardised, rigorous search and a Cochrane Review are required in this disease area. This issue is further compounded by the practical need to manage the acute pain crises, as well as chronic pain conditions, experienced by millions of people with SCD worldwide. Current pharmacological therapies produce too many unacceptable side effects, and as already stated, recommendations encourage the use of non-pharmacological methods in SCD pain management. A Cochrane Review of the current evidence regarding the effectiveness of TENS as a complementary therapy for managing pain in people with SCD will allow health professionals and researchers make informed decisions about the use of this treatment.
O B J E C T I V E S
To assess the effects of TENS for managing pain in people with SCD who experience pain crises or chronic pain (or both), along with any possible adverse effects.
M E T H O D S Criteria for considering studies for this review Types of studies
RCTs. Quasi-RCTs will also be included if sufficient evidence is provided to demonstrate that the treatment and control groups are similar at baseline. In reference to cross-over trials, as we are currently unaware of the long-term effects of these interventions, we are unable to determine whether the effects of the first intervention will interfere with those of the second. In order to avoid introducing this bias into the analysis, we will include only first-arm data from crossover trials, when available.
Types of participants
People with known SCD (SS, SC, Sβ and Sβ , proven by electrophoresis and sickle solubility test, with family studies or DNA tests as appropriate) of all ages and both sexes, in any setting.
Types of interventions
We will include all standard modes of TENS which includes biphasic or monophasic electrical current delivered in pulses in high frequency, low intensity or low frequency, high intensity or other standard modes that produce perceptible sensation at the area of application. We will exclude other modes of electrotherapy, TENS that was delivered in intensities that were barely perceptible. Eligible comparisons are:
• TENS with conventional treatment (e.g. analgesics) versus conventional treatment alone;
• TENS versus placebo (sham) TENS;
• TENS versus other non-pharmacological modalities for treatment of pain.
We do not plan to compare different intensities and frequencies of TENS as all standard modes of TENS which produce perceptible sensation at the area of application will be included in this review. Placebo (sham) TENS devices may look exactly similar to active TENS devices, but are deactivated and produce no current or may produce a brief period of stimulation at the beginning which fades out later. Due to the lack of perceptible stimulation in SHAM TENS, blinding of participants to the mode of treatment is almost impossible (Sluka 2013 ) and this represents a risk of bias to all sham-controlled trials of TENS (Gibson 2015).
Types of outcome measures
Primary outcomes 1. Pain relief * 2. Pain intensity (as assessed by visual analogue pain scale score (VAS) or other validated assessment tools for measuring pain intensity during the use of TENS) 3. Frequency of pain episodes * We aim to present data at two to four weeks and after four weeks post intervention. For long-term usage (e.g. for a period of one month) we will consider the outcome measures up to three months. We will consider pain relief as moderate (at least 30% pain relief over baseline) or substantial (at least 50% pain relief over baseline) as defined by IMMPACT guidelines (Dworkin 2008).
Secondary outcomes
1. Changes in consumption of analgesic and opioids during pain episodes 2. Changes in quality of life (QoL) (as measured by a validated scale)
3. Ability to cope with the activities of daily living (ADL) 4. Adverse effects of the intervention
Search methods for identification of studies
We will search for all relevant published and unpublished trials without restrictions on language, year or publication status. Regarding our use of Google Scholar, we will perform a Google Scholar Advanced search, sort the results based on relevance, and screen the first 100 search results for relevant studies.
Electronic searches

Searching other resources
For assistance in identifying ongoing or unpublished studies, we will contact study authors who have conducted prominent research in the relevant field regarding their ongoing studies or other relevant papers which may be eligible for inclusion. We will search research papers which cannot be directly included in this review (observational studies, systematic and narrative reviews, conference reports, etc.) for the citations of relevant studies which can be included. These papers will then be sought and assessed for possible inclusion.
Organisations that we will attempt to contact to request suggestions for studies are:
• NCCIH formerly known as NCCAM; Regarding grey literature, studies have shown that published studies often overestimate outcomes, compared to grey literature articles (Hopewell 2007). Moreover, exclusion of grey literature can result in systematic error, thus seriously threatening the validity of a systematic review (McAuley 2000) . Therefore, to avoid this risk of publication bias, we will search grey literature databases in our attempt to identify relevant studies and authors from conference proceedings. We propose to search the following databases (recommended in the Cochrane Handbook For Systematic Reviews of Interventions) for unpublished reports or articles which may be appropriate for inclusion in this systematic review (Higgins 2011a):
• OpenGrey (www.opengrey.eu/); • PsychEXTRA (www.apa.org/psycextra/); • The Grey Literature Report (http://greylit.org/); • The Agency for Healthcare Research and Quality ( www.ahrq.gov/);
• MedNar (http://mednar.com/mednar/desktop/en/ search.html). 
Data collection and analysis
Selection of studies
Two review authors (SP, MG) will independently assess the eligibility of the trials identified by the literature searches by completing a trial selection form that will be designed in accordance with the inclusion criteria. Each author will independently evaluate each title for inclusion. If we do not find the relevant information in the abstract, we will retrieve the relevant full text report(s), if published, in order to complete this task. The authors will select the trials approved by both authors for inclusion in the review. In the case of any discrepancies relating to eligibility, a third author (SKB) will arbitrate. We will tabulate the excluded trials under 'Characteristics of excluded studies' and reasons will be given for the exclusion. The review authors will be unmasked to the trial authors, institutions and trial results during their assessments. We will produce a PRISMA chart as a systematic illustration of the entire trial selection process.
Data extraction and management
Two review authors (SP, SM) will independently and simultaneously extract data from the selected articles and this will be verified by two or three review authors with an aim to resolve any disagreements by discussion and consensus. We will extract data using a standardised, pre-tested data extraction form. We will design the data extraction form through a collaboration of the review authors, and then pilot test this using a sample RCT and a quasi-RCT to ensure practical functionality. We will extract the following information from the included studies.
Trial characteristics and source
• Trial identifier (ID) -to be created by the review author • Report ID -to be created by the review author 
• Number of participants allocated to each intervention group
For each outcome of interest
• Sample size • Missing participants • Summary data for each intervention group (mean and standard deviation for continuous data, 2 x 2 contingency table for dichotomous data, etc.)
Assessment of risk of bias in included studies
Two review authors (RD, SM) will independently assess the risk of bias of the included studies by using the criteria outlined in chapter 8 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011b). Each study will be assessed according to the following five components.
1. Random sequence generation (selection bias) 2. Allocation concealment (selection bias) 3. Masking (blinding) of participants and personnel (performance bias), and masking of outcome assessment 4. Incomplete outcome data (attrition bias) through withdrawals, dropouts and protocol deviations; and 5. Selective reporting bias We will also assess for any other sources of bias as reported in the Cochrane Handbook for Systematic Reviews of Interventions (bias related to the specific study design, early or abrupt end of studies, fraudulent studies) (Higgins 2011b). For each of the mentioned components, we will assign judgements of either low, unclear or high risk of bias. We will record the results in the standard table provided in the Review Manager software (RevMan 2014), and will summarize the findings in a 'Risk of bias' table or graph. We aim to resolve any concerns or issues by discussion with a third review author (ALA). We will address the implications of the 'Risk of bias' assessment in the discussion section.
Measures of treatment effect
We will analyse and present dichotomous data, such as need for daily analgesic consumption between pain events, and ability to cope with ADL using the risk ratios (RR) with 95% confidence intervals (CIs). We will report adverse effects of the intervention with 99% CI to avoid errors due to multiple statistical testing. We will analyse and present continuous data, such as dose of analgesic consumption between pain events, pain relief and pain intensity as assessed by visual analogue pain scale score (on a scale of 0 to 10), improvements in quality of life (QoL), using the mean differences (MD) (if outcomes are measured using the same scales) along with their 95% CIs. If outcomes are measured using different scales, we will use the standardised MD (SMD) and corresponding 95% CIs. We will analyse and present count data, such as frequency of pain episodes using the MD, which they will calculate by comparing the difference in the mean number of events in the intervention group as compared to the control group. If they are rare events, we will present the results using the rate ratio with 95% CIs. Where meta analysis is not possible, we will present a narrative summary along with tabulated data.
Unit of analysis issues
The unit of analysis in this review will be the individual with SCD. Results of any identified cluster-randomised studies will be reported separately. Regarding cross-over trials, as we are currently unaware of the longterm effects of these interventions, we are unable to determine whether the effects of the first intervention will interfere with those of the second. In order to avoid introducing this bias into the analysis, we will include only first-arm data from cross-over trials, when available. If we identify trials with multiple treatment arms, we will only include those treatment arms whose parameters are minimally different from other included trials.
Dealing with missing data
We will contact trial authors to request access to the missing data regarding methods, participants, interventions and outcomes. In cases of missing data due to participant drop out we will conduct a primary analysis based on participants for whom complete data are available, provided that the total number of randomised participants and the number of dropouts to follow-up are well documented. We assume that missing outcomes will not be a problem if loss-to-follow-up is well documented, and is unrelated to outcomes in both trial arms, as per chapter 16 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011a). However, if the reasons for why the data are missing are not available, we will document the possible effects of the missing participants through a sensitivity analysis.
Assessment of heterogeneity
In order to deal with clinical heterogeneity, studies that examine similar interventions will be pooled together. We will perform separate analyses for TENS compared to conventional treatment and TENS compared to placebo TENS or other non-pharmacological treatment. If we identify substantial (or higher) heterogeneity, and provided there are sufficient data, then we will undertake subgroup analyses according to the pre-planned comparisons described in the section 'Subgroup analysis and investigation of heterogeneity'. We will use the Chi² test for assessing heterogeneity (significance level: P < 0.1). We will quantify the degree of heterogeneity using the I² statistic (Deeks 2008). The guidelines for interpretation of the I² values will be as follows.
• 0% to 40% indicates unimportant levels of heterogeneity • 30% to 60% indicates moderate heterogeneity • 50% to 90% indicates substantial heterogeneity • 75% to 100% indicates considerable heterogeneity
We will also consider a visual inspection of the forest plot to identify whether CIs overlap.
Assessment of reporting biases
As we anticipate the inclusion of trials from the grey literature, it is particularly important for us to conduct an assessment of publication bias. If we identify at least 10 trials for inclusion in a metaanalysis, we will explore potential publication bias by generating a funnel plot and performing Egger's test to determine the degree of asymmetry (Egger 1997) . If the included trials differ in sample size then we will visually inspect the funnel plots to explore the possibility of reporting biases. The results of Egger's test will also be interpreted cautiously due to the presence of many limitations in quantifying possible reporting biases (Moore 2008 ). We will address the implications of the publication bias assessment on the review findings in the discussion section.
Data synthesis
We will synthesize the quantitative data compiled using the data extraction forms using a meta-analysis. We will use continuous data to calculate a MD or SMD for use in the meta-analysis, depending on the scales of measurement used in the trials (according to the reasoning in 'Measures of treatment effect'). We will calculate the appropriate measure of association (e.g. RR) for estimation of relative risk using categorical data. The summary measures will be pooled as appropriate, according to the scales used in different trials. We will calculate the I² statistic to determine statistical heterogeneity, and thus determine whether a fixed-effect model (negligible heterogeneity), or a random-effects model (non-negligible heterogeneity) should be used for the meta-analysis (DerSimonian 1986). The results of the meta-analysis will be reported as pooled effect estimates, stated with 95% CIs and illustrated graphically in a forest plot. If meta-analysis cannot be undertaken for a particular outcome (due to an insufficient number of studies, or any other reason), we will include reasoning for this, as well as a narrative discussion of the available evidence relevant to the outcome variable in question.
Subgroup analysis and investigation of heterogeneity
If we identify substantial (or higher) statistical heterogeneity we plan the following subgroup analysis investigating the possible effect of TENS based on:
• age groups (below 18 years of age, 18 years and over);
• gender (male, female);
• stimulation parameters (e.g. high stimulation frequency with low intensity, low frequency with a high stimulus intensity);
• frequency of administration of TENS (e.g. daily or not on a daily basis);
• duration of treatment with TENS (e.g. 30-minute sessions or more than 30 minutes).
Sensitivity analysis
We will assess the robustness of our findings by performing sensitivity analyses according to Cochrane recommendations where appropriate (Deeks 2011). If there are sufficient comparable trials, i.e. 10 or more, we will perform sensitivity analyses to study the effect of excluding trials with high risks of bias due to inadequate allocation of concealment, blinding, randomisation method or level of dropouts. Furthermore, we will also consider the impact of using a fixed-effect model compared to a random-effects model.
Summary of findings table
We will use the GRADE approach to create a 'Summary of findings' table, as suggested in chapters 11 and 12 of the Cochrane Handbook for Systematic Reviews of Interventions (Schünemann 2011a; Schünemann 2011b). The table will present the trial population and setting, the type of intervention and control group, the outcome measures listed below and an assessment of the evidence quality (as measured by the GRADE approach). We will use the GRADE approach to rate the quality of the evidence as 'high', 'moderate', 'low', or 'very low' using the five GRADE considerations.
1. Risk of bias: serious or very serious 2. Inconsistency: serious or very serious 3. Indirectness: serious or very serious 4. Imprecision: serious or very serious 5. Publication bias: likely or very likely We will generate a separate 'Summary of findings' table for each comparison with the following outcomes:
• pain relief;
• pain intensity as assessed by VAS or any other validated pain score;
• frequency of pain episodes;
• changes in consumption of analgesics and opioids during pain episodes;
• changes in QoL (as measured by a validated scale);
• changes in ability to cope with the ADL;
• adverse effects of the intervention.
A C K N O W L E D G E M E N T S
We would like to thank: Tracey Remmington, Managing Editor, Cochrane Cystic Fibrosis and Genetic Disorders Review Group for providing guidance in drafting the protocol; Sarah Nevitt, Group Statistician, Cochrane Cystic Fibrosis and Genetic Disorders Review Group for providing guidance in drafting the protocol; Natalie Hall, Information Specialist, Cochrane Cystic Fibrosis and Genetic Disorders Review Group, for comments on the search strategy.
We are very grateful to Professor Datuk Dr Abdul Razzak Chief Executive of Melaka-Manipal Medical College, Malaysia and Professor Dr Jaspal Singh, Dean, Faculty of Medicine, Melaka-Manipal Medical College, Malaysia for their constant support, constructive comments and encouragement in writing this protocol. This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane Cystic Fibrosis and Genetic Disorders Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.
